| scholarly article | Q13442814 |
| P50 | author | Helen Hobbs | Q21433424 |
| Santica M Marcovina | Q91980709 | ||
| P2093 | author name string | M C Seabra | |
| V Mooser | |||
| M Abedin | |||
| K T Landschulz | |||
| P2860 | cites work | The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans | Q24562140 |
| Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects | Q28270269 | ||
| cDNA sequence of human apolipoprotein(a) is homologous to plasminogen | Q28302632 | ||
| Regulation of the very low density lipoprotein receptor by thyroid hormone in rat skeletal muscle | Q28567353 | ||
| Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma | Q29615947 | ||
| Molecular genetics of lipoprotein (a): new pieces to the puzzle | Q33367221 | ||
| Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. Evidence for no common "null" allele at the apo(a) locus | Q34151817 | ||
| Molecular characterisation of the human apo(a)-plasminogen gene family clustered on the telomeric region of chromosome 6 (6q26-27). | Q34328856 | ||
| Physical properties of recombinant apolipoprotein(a) and its association with LDL to form an LP(a)-like complex | Q36779775 | ||
| A functional domain in the heavy chain of scatter factor/hepatocyte growth factor binds the c-Met receptor and induces cell dissociation but not mitogenesis | Q37329953 | ||
| The unique lipoprotein(a): properties and immunochemical measurement | Q38005421 | ||
| Kringle 4 of human apolipoprotein[a] shares a linear antigenic site with human catalase. | Q42675533 | ||
| Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA. | Q46141209 | ||
| Rhesus monkey apolipoprotein(a). Sequence, evolution, and sites of synthesis | Q46623122 | ||
| Molecular definition of the extreme size polymorphism in apolipoprotein(a). | Q47390927 | ||
| Plasma lipoprotein(a) concentration is controlled by apolipoprotein(a) (apo(a)) protein size and the abundance of hepatic apo(a) mRNA in a cynomolgus monkey model | Q47427374 | ||
| Loss of a splice donor site at a 'skipped exon' in a gene homologous to apolipoprotein(a) leads to an mRNA encoding a protein consisting of a single kringle domain | Q48076329 | ||
| Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. | Q51596475 | ||
| Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a) | Q54255867 | ||
| Characterization of polymerase chain reaction amplification of specific alleles | Q61820216 | ||
| Quantitation and localization of apolipoproteins [a] and B in coronary artery bypass vein grafts resected at re-operation | Q63983785 | ||
| Detection and quantitation of apolipoprotein(a) mRNA in human liver and its relationship with plasma lipoprotein(a) concentration | Q67907542 | ||
| Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure | Q67921466 | ||
| Lipoprotein(a) in heart disease | Q68055938 | ||
| Physicochemical properties of apolipoprotein(a) and lipoprotein(a-) derived from the dissociation of human plasma lipoprotein (a) | Q69996711 | ||
| Lipoprotein[a] is the major apoB-containing lipoprotein in the plasma of a hibernator, the hedgehog (Erinaceus europaeus) | Q70063622 | ||
| Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies | Q70603384 | ||
| Intracellular maturation of apolipoprotein[a] and assembly of lipoprotein[a] in primary baboon hepatocytes | Q70649140 | ||
| Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a) | Q71676941 | ||
| Extraction of lipoprotein(a), apo B, and apo E from fresh human arterial wall and atherosclerotic plaques | Q71858695 | ||
| Autocrine stimulation of motility in SBC-5 human lung carcinoma cells by a two-kringle variant of HGF | Q72132702 | ||
| Structural domains of apolipoprotein(a) and its interaction with apolipoprotein B-100 in the lipoprotein(a) particle | Q72311761 | ||
| Lp(a) catabolism in hypercholesterolaemic individuals | Q72428841 | ||
| Immunochemically detectable lipid-free apo(a) in plasma and in human atherosclerotic lesions | Q72428859 | ||
| Lipoprotein(a) in nonhuman primates. Presence and characteristics of Lp(a) immunoreactive materials using anti-human Lp(a) serum | Q93515702 | ||
| Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients | Q93520879 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lipoprotein | Q28350 |
| LPA | Q18028636 | ||
| P304 | page(s) | 858-864 | |
| P577 | publication date | 1996-02-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). | |
| P478 | volume | 97 |
| Q43789030 | Aminoalkyl affinity matrices |
| Q44562485 | Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation |
| Q77569207 | Atherothrombogenicity of lipoprotein(a): the debate |
| Q33544622 | Biochemical risk factors and patient's outcome: the case of lipoprotein(a). |
| Q47729039 | Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. |
| Q33958895 | Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix |
| Q35879090 | Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease |
| Q47403340 | In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent |
| Q92814248 | In-Depth Mapping of the Urinary N-Glycoproteome: Distinct Signatures of ccRCC-related Progression |
| Q73961084 | Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease |
| Q53655587 | Inhibition of Angiogenesis and Angiogenesis-dependent Tumor Growth by the Cryptic Kringle Fragments of Human Apolipoprotein(a) |
| Q37361631 | Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine |
| Q46693462 | Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. |
| Q34027241 | Lipoprotein(a) and coronary heart disease risk |
| Q77700147 | Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation |
| Q77896432 | Lipoprotein(a) as a risk factor for coronary artery disease |
| Q41300659 | Lipoprotein(a) in health and disease |
| Q36539756 | Lipoprotein(a) metabolism: potential sites for therapeutic targets |
| Q78004696 | Lipoprotein(a) plasma concentrations after renal transplantation: a prospective evaluation after 4 years of follow-up |
| Q35081894 | Lipoprotein(a): an emerging cardiovascular risk factor |
| Q38045424 | Lipoprotein(a): resurrected by genetics |
| Q28140467 | Macrophage metalloelastase, MMP-12, cleaves human apolipoprotein(a) in the linker region between kringles IV-4 and IV-5. Potential relevance to lipoprotein(a) biology |
| Q41564035 | Pathophysiological implication of the structural domains of lipoprotein(a). |
| Q35746865 | Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints |
| Q28235516 | Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments |
| Q73318670 | Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men |
| Q43650906 | Role of various tissues in apo(a) fragmentation and excretion of fragments by the kidney |
| Q44562856 | Standardization and clinical management of lipoprotein(a) measurements |
| Q28211363 | Structural elucidation of the N- and O-glycans of human apolipoprotein(a): role of o-glycans in conferring protease resistance |
| Q37374146 | The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor |
| Q49598174 | The role of lipoprotein (a) in chronic kidney disease |
| Q58071851 | Urinary apo(a) discriminates coronary artery disease patients from controls |
| Q58071802 | Urinary apolipoprotein (a) excretion in patients with proteinuria |
| Q58071705 | Urinary excretion of apolipoprotein(a): relation to other plasma proteins |
Search more.